

Severe Problems

- Serious allergic reaction (very rare)

6. What If There Is a Moderate or Severe Reaction?

What Should I Look For?

Any unusual condition, such as a serious allergic reaction, high fever or behavior changes. Signs of a serious allergic reaction can include difficulty breathing, hoarseness or wheezing, hives, paleness, weakness, a fast heart beat or dizziness. If such a reaction were to occur, it would be within a few minutes to a few hours after the shot.

What Should I Do?

- Call a doctor or get the person to a doctor right away.
- Tell your doctor what happened, the date and time it happened, and when the vaccination was given.
- Ask your doctor, nurse, or health department to file a Vaccine Adverse Event Reporting System (VAERS) form, or call VAERS yourself at 1-800-822-7967.

7. The National Vaccine Injury Compensation Program

In the rare event that you or your child has a serious reaction to a vaccine, a federal program has been created to help pay for the care of those who have been harmed.

For details about the National Vaccine Injury Compensation Program, call 1-800-338-2382 or visit the program's website at <http://www.hrsa.gov/bhpr/vicp>

8. How Can I Learn More?

- Ask your doctor or nurse. They can give you the vaccine package insert or suggest other sources of information.
- Call your local or state health department's immunization program.
- Contact the Centers for Disease Control and Prevention (CDC):
—Call 1-800-232-2522 or 1-888-443-7232 (English)
—Call 1-800-232-0233 (Español)
—Visit the National Immunization Program's website at <http://www.cdc.gov/nip> or CDC's Hepatitis Branch website at <http://www.cdc.gov/ncidod/diseases/hepatitis>

Department of Health & Human Services, Centers for Disease Control and Prevention, National Immunization Program

Vaccine Information Statement
Hepatitis B
(00/00/0000) (Proposed)
42 U.S.C. 300aa-26

Dated: February 28, 2001.

Joseph R. Carter,

Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 01-5377 Filed 3-5-01; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N-1168]

Relative Risk to Public Health From Foodborne *Listeria Monocytogenes* Among Selected Categories of Ready-to-Eat Foods; Draft Risk Assessment Document and Risk Management Action Plan; Public Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting.

The Food and Drug Administration (FDA), in cooperation with the Food Safety and Inspection Service (FSIS) of the U.S. Department of Agriculture (USDA), and the Centers for Disease Control and Prevention is announcing the following public meeting: Relative Risk to Public Health from Foodborne *Listeria Monocytogenes* Among Selected Categories of Ready-to-Eat Foods; Draft Risk Assessment Document and Risk Management Action Plan. The purpose of the public meeting is to receive comments on the technical aspects of a draft risk assessment on the relationship between foodborne *Listeria monocytogenes* and human health, and on a proposed risk management action plan for *L. monocytogenes*. A notice of availability of the draft risk assessment and the action plan was published in the **Federal Register** of January 19, 2001 (66 FR 5515).

Date and Time: The meeting will be held on March 19, 2001, 8:30 a.m. to 4 p.m.

Location: The meeting will be held at the Hilton Hotel, 2399 Jefferson Davis Hwy., Arlington, VA 22202.

Contact: Catherine M. DeRoever, Center for Food Safety and Applied Nutrition (HFS-6), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-205-4251, FAX 202-205-4970, e-mail: cderoeve@cfsan.fda.gov.

Registration and Requests for Oral Presentations: Send registration information (including name, title, firm name, address, telephone, and fax number), to the contact person by March 14, 2001. Interested persons may present data, information, or views

orally or in writing, on the issues identified above. Written submissions must also be made to the contact person by March 14, 2001. Time allotted for each presentation may be limited. If you wish to make a formal oral presentation, you should notify the contact person before March 14, 2001, and be prepared to provide a brief statement of the general nature of the evidence you wish to present.

If you need special accommodations due to a disability, please contact Catherine M. DeRoever (address above) at least 7 days in advance.

Transcripts: Transcripts of the meeting may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page.

SUPPLEMENTARY INFORMATION: The U. S. Department of Health and Human Services and the USDA are seeking comments on the technical aspects of the draft risk assessment in the following areas: (1) The assumptions made, (2) the modeling technique, (3) the data used, and (4) the transparency of the draft risk assessment document. All public comments will be reviewed and evaluated, and the assessment will be modified, as appropriate. The agencies are also inviting comments on the risk management strategies as presented in the draft action plan.

Dated: February 28, 2001.

Ann M Witt,

Acting Associate Commissioner for Policy.

[FR Doc. 01-5379 Filed 3-1-01; 4:23 pm]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N-1075]

Public Health Impact of *Vibrio Parahaemolyticus* in Raw Molluscan Shellfish; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting on: *Vibrio parahaemolyticus* in raw molluscan shellfish and human health. The purpose of the meeting is to receive comments on the technical aspects of the draft risk assessment on the relationship between *Vibrio parahaemolyticus* in raw molluscan